GSK's Vaccine Weakness Is a Major Concern -- Market Talk

Dow Jones10-30

0822 GMT - GSK's vaccine weakness is the major concern among its 3Q results and could threaten the company's mid-term sales outlook, Intron Health analysts say in a note. The British Pharma giant confirmed its 2024 outlook, including its overall sales forecast. However, it cut annual vaccine sales guidance to low-single digits, from its prior low to mid-single digit range. The vaccine sales target cut follows a 21% miss by its respiratory syncytial virus vaccine Arexvy and a 13% miss by its best-selling shingles vaccine Shingrix, analysts say. "Our biggest concern is the impact on mid-term sales growth from the weakening vaccines outlook and cost increases ahead of new launches next year," they say. Shares are down 2.1% at 14.22 pounds. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

October 30, 2024 04:22 ET (08:22 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479297722?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 16:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479297722","market":"fut","top_or_hot":-1,"title":"GSK's Vaccine Weakness Is a Major Concern -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0822 GMT - GSK's vaccine weakness is the major concern among its 3Q results and could threaten the company's mid-term sales outlook, Intron Health analysts say in a note. The British Pharma giant confirmed its 2024 outlook, including its overall sales forecast. However, it cut annual vaccine sales guidance to low-single digits, from its prior low to mid-single digit range. The vaccine sales target cut follows a 21% miss by its respiratory syncytial virus vaccine Arexvy and a 13% miss by its best-selling shingles vaccine Shingrix, analysts say. \"Our biggest concern is the impact on mid-term sales growth from the weakening vaccines outlook and cost increases ahead of new launches next year,\" they say. Shares are down 2.1% at 14.22 pounds. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2024 04:22 ET (08:22 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK's Vaccine Weakness Is a Major Concern -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK's Vaccine Weakness Is a Major Concern -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 16:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0822 GMT - GSK's vaccine weakness is the major concern among its 3Q results and could threaten the company's mid-term sales outlook, Intron Health analysts say in a note. The British Pharma giant ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479297722","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479297722","pubTimestamp":1730276520,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0822 GMT - GSK's vaccine weakness is the major concern among its 3Q results and could threaten the company's mid-term sales outlook, Intron Health analysts say in a note. The British Pharma giant confirmed its 2024 outlook, including its overall sales forecast. However, it cut annual vaccine sales guidance to low-single digits, from its prior low to mid-single digit range. The vaccine sales target cut follows a 21% miss by its respiratory syncytial virus vaccine Arexvy and a 13% miss by its best-selling shingles vaccine Shingrix, analysts say. \"Our biggest concern is the impact on mid-term sales growth from the weakening vaccines outlook and cost increases ahead of new launches next year,\" they say. Shares are down 2.1% at 14.22 pounds. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","GSK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","GSK.UK":"葛兰素史克","BK4532":"文艺复兴科技持仓"},"translate_title":"葛兰素史克的疫苗弱点是一个主要问题——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1,"GSK.UK":0.6},"content_text":"0822 GMT - GSK's vaccine weakness is the major concern among its 3Q results and could threaten the company's mid-term sales outlook, Intron Health analysts say in a note. The British Pharma giant confirmed its 2024 outlook, including its overall sales forecast. However, it cut annual vaccine sales guidance to low-single digits, from its prior low to mid-single digit range. The vaccine sales target cut follows a 21% miss by its respiratory syncytial virus vaccine Arexvy and a 13% miss by its best-selling shingles vaccine Shingrix, analysts say. \"Our biggest concern is the impact on mid-term sales growth from the weakening vaccines outlook and cost increases ahead of new launches next year,\" they say. Shares are down 2.1% at 14.22 pounds. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2024 04:22 ET (08:22 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479297722"}